3. Novavax (NVAX) develops recombinant vaccines for infectious diseases including influenza. Its second-quarter net loss expanded 10% to $9.4 million, but the per share loss contracted to 8 cents. Revenue dropped 76%. Novavax has $27 million of cash and $440,000 of debt. Its stock trades at a book value multiple of 4.1, a 23% discount to the biotech industry average. It's expensive based on sales. All five of the analysts researching Novavax recommend purchasing its shares. A median price target of $7.06 implies that the stock will triple in 12 months.
Bullish Scenario: McNicoll, Lewis & Vlak expects Novavax's stock to more than quadruple to $11.